# Bright Minds Biosciences Inc.: overview DRUG · Nasdaq · CIK 1827401 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/drug.md) · [Financials](/companies/drug/financials.md) · [Filings](/companies/drug/filings.md) · [Insiders](/companies/drug/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2020-09-30) | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.13)](/filings/0001062993-22-024547.md) | [(4.82)](/filings/0001062993-23-023281.md) | [(6.06)](/filings/0001062993-24-021301.md) | [(1.98)](/filings/0001062993-24-021301.md) | [(0.65)](/filings/0001062993-24-021301.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/drug/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $94.8m | 1,349,107 | | Not compared | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $93.5m | 1,284,324 | | Not compared | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $63.2m | 900,000 | | Reduced −159,331 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $48.2m | 686,184 | | Added +64,251 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $39.1m | 557,172 | | Unchanged | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $38.3m | 545,000 | | Added +52,681 | | [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $34.0m | 483,822 | | Reduced −55,886 | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $30.4m | 433,377 | | Added +862 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $24.2m | 345,053 | | Added +47,895 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $23.5m | 335,000 | | Reduced −160,743 | ## Recent filings [All 179 filings](/companies/drug/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 21:14 ET | [6-K](/filings/0001062993-26-005170.md) | Report of a foreign private issuer, period 2026-03-31 | 0001062993-26-005170 | | 2026-10-01 | 22:25 ET | [6-K](/filings/0001062993-26-005123.md) | Report of a foreign private issuer, period 2026-09-30 | 0001062993-26-005123 | | 2026-08-17 | 22:37 ET | [6-K](/filings/0001062993-26-004442.md) | Report of a foreign private issuer, period 2026-06-30 | 0001062993-26-004442 | | 2026-07-02 | 21:23 ET | [SCHEDULE 13D/A](/filings/0001062993-26-003506.md) | Ownership report, active investor, amended | 0001062993-26-003506 | | 2026-06-03 | 10:01 ET | [6-K](/filings/0001062993-26-003005.md) | Report of a foreign private issuer, period 2026-03-31 | 0001062993-26-003005 | | 2026-06-02 | 15:38 ET | [6-K](/filings/0001062993-26-002975.md) | Report of a foreign private issuer, period 2026-01-20 | 0001062993-26-002975 | | 2026-05-28 | 00:03 ET | [6-K](/filings/0002060755-26-000031.md) | Report of a foreign private issuer, period 2026-05-26 | 0002060755-26-000031 | | 2026-05-20 | 22:15 ET | [6-K](/filings/0001062993-26-002801.md) | Report of a foreign private issuer, period 2026-03-31 | 0001062993-26-002801 | | 2026-02-13 | 11:04 ET | [6-K](/filings/0001062993-26-000881.md) | Report of a foreign private issuer, period 2025-12-31 | 0001062993-26-000881 | | 2026-01-09 | 21:11 ET | [6-K](/filings/0001062993-26-000151.md) | Report of a foreign private issuer, period 2026-01-09 | 0001062993-26-000151 | ## Latest annual report [Form 40-F for the fiscal year ended Sep 30, 2025](/filings/0001437749-25-038729.md), filed Dec 23, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1827401 - Tickers: DRUG - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.